Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of therapies for the treatment of autoimmune diseases. The company's lead product is called voclosporin, which is a calcineurin inhibitor that is currently being developed for the treatment of lupus nephritis, a serious autoimmune disease that affects the kidneys.

Aurinia Pharmaceuticals was founded in 1993 and is headquartered in Victoria, British Columbia, Canada. The company's mission is to improve the lives of people with autoimmune diseases by developing innovative and effective therapies. Aurinia Pharmaceuticals has a team of experienced scientists, researchers, and business professionals who are dedicated to advancing the company's pipeline of drug candidates.

In addition to voclosporin, Aurinia Pharmaceuticals has several other drug candidates in its pipeline, including a therapeutic antibody for the treatment of IgA nephropathy, a chronic kidney disease. The company is also exploring the potential of its technology platform to develop therapies for other autoimmune diseases, such as multiple sclerosis and psoriasis.

Overall, Aurinia Pharmaceuticals is a promising company that is focused on developing innovative therapies for the treatment of autoimmune diseases. With a strong pipeline of drug candidates and a dedicated team of professionals, the company is well-positioned to make a significant impact in the field of biopharmaceuticals.

Founded: 1993

Headquarters: Victoria, Canada

Website: https://www.auriniapharma.com/